Hypoglycaemia risk requires consideration, particularly in patients with type 2 diabetes taking GLP-1 medications alongside insulin or sulfonylureas
Regular weight checks and progress reports
Diabetic macular edema (DME)
Triple agonists add glucagon receptor activation, which: Increases resting energy expenditure by 8% to 12% (Jall et al., Diabetes Care 2024) Promotes hepatic fat oxidation and reduces steatosis May offset some of the lean mass loss seen with GLP-1 monotherapy (early signal, not yet confirmed in long-term trials) The weight loss ceiling for retatrutide appears to be 24% to 26% based on phase 3 data, though long-term real-world outcomes are not yet available
Delayed Gastric Emptying For many patients pursuing S emaglutide weight loss in Denver , one key mechanism behind its effectiveness is delayed gastric emptying
Residual unreacted HSA was removed by three consecutive pulses of 9 s with 25 mM NaOH (3 l), resulting in a surface of 14,360 RFU
